SEC Form 4 · accession 0001209191-17-047716
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Chodakewitz
Officer — EVP GMDA, CMO
Period of report
Aug 2, 2017
Accepted (ET)
Aug 4, 2017 · 4:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 2, 2017 | M | 1,796 | $91.05 | A | 116,220 | D | |
| Common StockF2,F3 | Aug 2, 2017 | S | 500 | $152.50 | D | 115,720 | D | |
| Common StockF3,F4 | Aug 2, 2017 | S | 600 | $153.93 | D | 115,120 | D | |
| Common StockF3,F5 | Aug 2, 2017 | S | 400 | $154.89 | D | 114,720 | D | |
| Common StockF3,F6 | Aug 2, 2017 | S | 296 | $156.24 | D | 114,424 | D | |
| Common Stock | Aug 3, 2017 | M | 3,594 | $109.14 | A | 118,018 | D | |
| Common StockF3,F7 | Aug 3, 2017 | S | 600 | $153.29 | D | 117,418 | D | |
| Common StockF3,F8 | Aug 3, 2017 | S | 2,494 | $154.21 | D | 114,924 | D | |
| Common StockF3,F9 | Aug 3, 2017 | S | 500 | $155.15 | D | 114,424 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F10 | $91.05 | Aug 2, 2017 | M | 1,796 | D | — | Feb 1, 2026 | Common Stock | 1,796 | 17,960 | D |
| Stock Option (Right to Buy)F11 | $109.14 | Aug 3, 2017 | M | 3,594 | D | — | Feb 2, 2025 | Common Stock | 3,594 | 21,563 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
- F10The option vests in 16 quarterly installments from 2/2/2016.
- F11The option vests in 16 quarterly installments from 2/3/2015.
- F2Open market sales reported on this line occurred at a weighted average price of $152.50 (range $152.00 to $152.88).
- F3Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $153.93 (range $153.31 to $154.30).
- F5Open market sales reported on this line occurred at a weighted average price of $154.89 (range $154.70 to $155.40).
- F6Open market sales reported on this line occurred at a weighted average price of $156.24 (range $155.94 to $156.40).
- F7Open market sales reported on this line occurred at a weighted average price of $153.29 (range $152.63 to $153.55).
- F8Open market sales reported on this line occurred at a weighted average price of $154.21 (range $153.71 to $154.64).
- F9Open market sales reported on this line occurred at a weighted average price of $155.15 (range $154.73 to $155.53).